Diplomat, the country's largest independent specialty pharmacy, announced today it is one of five specialty pharmacies selected as a provider of IMBRUVICA™ (ibrutinib) capsules, approved Nov. 13 by the U.S. Food and Drug Administration (FDA) for the treatment of Mantle Cell Lymphoma (MCL).
IMBRUVICA™, a Brutton's Tyrosine Kinase (BTK) Inhibitor, is an oral drug available in 140 mg, 90 capsule bottles and 140 mg, 120 capsule bottles. Full prescribing information is available at www.IMBRUVICA.com.
"We are pleased to partner with Pharmacyclics and Janssen Biotech, Inc. as a specialty pharmacy provider of IMBRUVICA™," said Gary Kadlec, R.Ph., President of Diplomat. "Diplomat has proven expertise in handling limited distribution drugs and an industry-wide reputation for comprehensive patient care outreach that improves patient compliance, adherence and outcomes."
Diplomat's high-tech, high-touch approach, which achieved 98% patient and prescriber satisfaction ratings in 2012, includes timely prescription delivery, side effect management support and 24 hour access to pharmacists and other specialists on the continuum of care. For IMBRUVICA™, Diplomat will also provide prior authorization management, co-pay support, and assistance to patients that meet certain financial criteria.
IMBRUVICA™ is commercially available immediately.
Scientists map all yeast proteins across cell cycle for the first time